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Brain metastasis is an end stage in breast cancer progression. Traditional treatment options have minimal
efficacy, and overall survival is on the order ofmonths. The incidence of brainmetastatic disease is increasing
with the improvedmanagement of systemic disease and prolongation of survival. Unfortunately, the targeted
therapies that control systemic disease have diminished efficacy against brain lesions. There are reasons to
be optimistic, however, as emerging therapies have shown promise in preclinical and early clinical settings.
This review discusses recent advances in breast cancer brain metastasis therapy and potential approaches
for successful treatment.The incidence of breast cancer brain metastases (BCBM) varies
with the subtype of disease. Whereas patients with estrogen re-
ceptor (ER)-positive, human epidermal growth factor receptor-2
(HER2)-negative tumors (70% of breast cancers) have a brain
metastasis incidence of 5%–10%, those with triple-negative or
HER2-positive tumors have an incidence rate about 20% and
25%–50%, respectively (Kennecke et al., 2010; Aversa et al.,
2014). The high incidence rate for patients with HER2-positive
disease is likely due to several factors including the ability of
HER2 to increase the proclivity of brain metastases (BM), but is
almost certainly due to the prolongation of survival resulting
from anti-HER2-targeted therapies (Brufsky et al., 2011b; Gori
et al., 2007; Olson et al., 2013). Prognosis is affected by various
factors, including the number of BM, the presence of active
extracranial disease, the patient’s age and performance status,
and the tumor subtype (Sperduto et al., 2012, 2013). These
factors also affect treatment regimens. In the majority of cases,
treatment is palliative and mostly local, such as surgical resec-
tion, stereotactic radiosurgery, and/or whole brain irradiation
(WBRT) (Eichler et al., 2011). Survival duration varies between
4-6 months with WBRT to about 18 months with multimodal
therapies (Kocher et al., 2011). The poor prognosis with local
therapies, and the fact that most patients with BCBM display
synchronous extracranial disease, underscores the need for
better systemic treatments with efficacy in the cerebral micro-
environment. Over the last few years, preclinical and
clinical progress in the treatment of BCBM has led to novel
hypotheses for improving therapeutic outcome. This review
focuses on these discoveries, separates those confirmed in
patients from those still preclinical, distinguishes between pre-
ventative and treatment strategies, and suggests avenues for
future investigation.
Can Breast Cancer Brain Metastases Be Prevented?
Animal models of BM have provided insights into processes
of the brain-metastatic cascade: dissemination of metastasis-
competent cells from the primary tumor, intravasation into the
blood circulation, active or passive migration toward the target
organ, embedding into a capillary bed and attachment to theendothelium, extravasation through the blood-brain barrier
(BBB), and expansion in the brain microenvironment (Figure 1)
(Eichler et al., 2011). Once arrested within the capillary bed of
the brain circulation, metastatic cancer cells come in contact
with brain microvascular endothelial cells, which promote
cancer cell growth and invasion. Real-time imaging of a murine
brain metastasis model showed early extravasation and persis-
tent contact with microvessels as necessary elements for colo-
nization (Kienast et al., 2010). A separate study identified the
cell adhesion molecule L1 (L1CAM) as necessary for vascular
co-option and, therefore, metastatic cancer cell survival and
tumor initiation in the brain microenvironment (Valiente et al.,
2014).
The majority of preclinical studies focus on early stages of
BCBM. This is mainly due to the fact that the knowledge gained
from preclinical studies is limited to the models and treatment
methods employed. While models of spontaneous brain metas-
tasis from intramammary implanted breast cancer cells exist, the
majority of knowledge has been gained from intracardiac, intra-
carotid, or intracranial injection models that forgo invasion and
migratory escape from the primary tumor environs. Multiple
selection rounds of brain metastatic lesions after mammary fat
pad, intracarotid, or intracardiac injection have generated
‘‘brain-seeking’’ clonal sublines. Gene expression analysis be-
tween brain-seeking and parental lines identified genes involved
in the early stages of the BCBM cascade. Furthermore, the ma-
jority of studies involved treatments initiated before the estab-
lishment of BCBM. Analysis of the initial steps of brainmetastatic
colonization revealed that intravascularly injected cancer cells
colonize the brain beginning at day 7–10 postinjection (Kienast
et al., 2010; Lorger and Felding-Habermann, 2010). Treatment
studies that begin prior to colonization translate, clinically, into
prevention studies. Table 1 summarizes salient findings from
preclinical prevention studies for each of the specific process
of the brain metastatic cascade (Figure 1). If preventative mea-
sures are to succeed in the clinic, methods to identify predis-
posed patients are necessary, and this will entail identification
of the expression of relevant proteins in primary or systemic me-
tastases of patient tissue. In addition to biopsy or resectedCancer Cell 27, February 9, 2015 ª2015 Elsevier Inc. 163
Figure 1. Schematic of Notable Targets of BCBM Formation Identified in Preclinical Studies
Molecules are categorized based on the stage of the metastatic cascade in which they are involved. Brain-tropic circulating tumor cells (CTCs) may express a
particular signature, such as EpCAM-/HER2+/EGFR+/HPSE+/Notch1+ (Zhang et al., 2013). While drug delivery into brain metastatic lesions is compromised by
the blood-tumor barrier (BTB), the ease of access is greater than in the normal brain (with an intact BBB). Methods used to enhance drug delivery are also
mentioned. Table 1 provides more detail on each target.
Cancer Cell
Perspectivetissue, circulating tumor cells (CTCs) have important prognostic
and therapeutic implications in the prevention setting. Zhang
et al. (2013) identified a potential signature of BCBM in human
CTCs that has the potential to identify patients susceptible to
brain metastatic disease.
Studies investigating the biology of established metastatic
lesions and its interaction with the microenvironment are
beginning to provide important knowledge about brain coloniza-
tion. Once infiltrated into the brain tissue, breast cancer cells
encounter a number of host cell types, including pericytes,
reactive glia, neural progenitor cells, neurons, and oligodendro-
cytes. Although the survival of neurons is reduced by growing
BM (Fitzgerald et al., 2012), there are no studies implicating
neurons, oligodendrocytes, or pericytes in BM formation. Peri-
cytes are present in BM (Lorger and Felding-Habermann,
2010) and play a significant role in the vasculature of primary
brain tumors (Armulik et al., 2011; Cheng et al., 2013). More is
known about the role of astrocytes and microglia that surround
and infiltrate brain metastatic lesions (Fitzgerald et al., 2008;
Lorger and Felding-Habermann, 2010). Analysis of human
BCBM shows an abundance of activated astrocytes and micro-
glia around and within the lesion (Zhang and Olsson, 1995). The
initial survival of brain metastatic cells seems to depend on their
ability to evade astrocyte-induced cell death (Valiente et al.,164 Cancer Cell 27, February 9, 2015 ª2015 Elsevier Inc.2014). The cells that survive take advantage of the growth-
permissive microenvironment. Preclinical studies have begun
to unravel the effect of the brain microenvironment on cancer
cells, including its ability to reprogram the gene expression pat-
terns of different cancer cell types (Park et al., 2011). Gene
signature analysis revealed alterations in pathways such as pro-
liferation, cell death, and metabolism in breast cancer cells. As-
trocytes, alone, can alter the gene expression of breast and lung
cancer cells and can promote resistance to chemotherapy
through activation of the endothelin axis (Kim et al., 2011,
2014). Recent findings demonstrated that tumor cells can in-
crease the density of growth-permissive astrocytes by promot-
ing the differentiation of neural progenitor cells into astrocytes
(Neman et al., 2013). Although the outcome of microglia infiltra-
tion is less known, microglia activation is inversely correlated
with the growth of breast cancer cells in the brain (Louie
et al., 2013). In summary, the brain microenvironment clearly of-
fers a unique milieu in which metastatic cancer cells can survive
and proliferate. Pathways altered by the microenvironment that
mediate therapeutic resistance are beginning to emerge.
Furthermore, clinical BM tissue has been shown to contain car-
cinoma-associated fibroblasts—not resident to the brain—that
could play a significant role in colonization and treatment resis-
tance (Duda et al., 2010).
Table 1. Preclinical Studies of BCBM
Targeta Targeting Methodb Modelc Outcome Commentsd References
Human epidermal growth
factor receptor 2 (HER2)
trastuzumab MDA-MB-361HK/intracranial
(leptomeningial injection)
decreased
BM/increased
survival
trastuzumab can normalize
tumor vessels
Izumi et al., 2002
Human epidermal growth
factor receptor 2 (HER2)
trastuzumab MCF-7-HER2/intracranial
injection of athymic rat
increased survival direct intracerebral
microinfusion
Grossi et al., 2003
Vascular endothelial growth
factor receptor (VEGFR)
PTK787/Z 222584
(RTK inhibitor)
MDA-231-BR3/intracarotid decreased BM/no
survival benefit
brain-seeking clones
express more VEGF-A
Kim et al., 2004
Matrix-metalloproteinase
2 (Mmp2)
TIMP2 ENU1564 rat mammary
adenocarcinoma
cells/intraventricular
Decreased BM TIMP2 expression decreases
primary tumor growth as well
Mendes et al., 2007
Immunostimulatory CpG CpG oligodeoxynucleotides
(ODN)
EMT6 murine mammary
carcinoma cells/intracranial
injection of CpG-ODN
challenged mice
decreased BM induction of protective immunity
in the brain; no beneficial effect
on established BM
Xiong et al., 2008
Histone deacetylase (HDAC) vorinostat MDA-MB-231-BR/intracranial decreased
BM/increased
survival
combination of vorinostat with
radiotherapy conveys better
survival and further decreased
BM when compared to
monotherapy; treatment study
Baschnagel et al., 2009
Alpha-N-acetylgalactosaminide
alpha-2,6-sialyltransferase
5 ST6GALNAC5
shRNA CN34-BrM2c/intracardiac decreased
BM/increased
survival
ST6GALNAC5 expression
enhances adhesion to brain
endothelial cells and promotes
passage through the BBB;
addition of cetuximab
(anti-EGFR antibody) further
reduces BM; increased expression
in BM clinical tissue
Bos et al., 2009
Integrin avb3 plasmid-mediated
expression of
avb3 (non-activated)
MDA-MB-435/intracranial decreased BM tumor cell integrin avb3 activation
increases angiogenesis and
decreases hypoxia
Lorger et al., 2009
Histone deacetylase (HDAC) vorinostat MDA-MB-231-BR/intracardiac decreased BM no significant decrease in BM
observed when treatment is
delayed to 18 days post-injection
Palmieri et al., 2009
Phosphodiesterase 5 (PDE5)
and human epidermal growth
factor receptor 2 (HER2)
vardenafil and
trastuzumab
BT-474/intracranial increased survival PDE5 inhibition increases
trastuzumab delivery in brain;
treatment study
Hu et al., 2010
Caveolin-1 (CAV1) and signal
transducer and activator of
transcription 3 (STAT3)
suppressor of cytokine
signaling 1 (SOCS1)
expression
MDA-MB-231-BR/intracarotid decreased BM SOCS-1 regulates Stat3 expression;
Stat3 regulates Caveolin-1
expression; increased pStat3 and
decreased caveolin-1 expression
in BM clinical tissue
Chiu et al., 2011
(Continued on next page)
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Table 1. Continued
Targeta Targeting Methodb Modelc Outcome Commentsd References
B-Raf proto-oncogene,
serine/threonine kinase
(BRAF)
pazopanib MDA-MB-231-BR-HER2
and MCF7-HER2-BR3/intracardiac
decreased BM pazopanib does not alter
vasculature
Gril et al., 2011
NOTCH1 shRNA or DAPT
(gamma secretase
inhibitor)
CD44hi_CD24lo_MDA-MB-231-BR/
intracardiac
decreased BM DAPT effective in treating
established BM lesions (14 days
post injection); treatment study
McGowan et al., 2011
Polo-like kinase 1 (PLK1) GSK461364A MDA-MB-231-BR/intracardiac decreased
BM/increased
survival
GSK461364A sensitizes cells
to radiation; delayed delivery
of GSK461364A (13 days) also
promotes survival; increased
expression in BM clinical tissue;
treatment study
Qian et al., 2011
Heparanase (HPSE) microRNA-1258 MDA-MB-231-BR3/intracardiac decreased BM effect of miR-1258 partly rescued
by HPSE overexpression; increased
HPSE and decreased miRNA-1258
expression in BM clinical tissue
Zhang et al., 2011
Microtubules TPI-287 MDA-MB-231-BR/intracardiac decreased BM no significant decrease in BM
observed when treatment delayed
to 18 days post-injection
Fitzgerald et al., 2012
Pigment epithelium-derived
factor (PEDF)
plasmid-mediated
expression
murine 4T1-BR/intracardiac decreased BM PEDF previously identified in gene
array with human BM tissue; PEDF
promotes neuronal survival around
BM lesion; PDEF is downregulated
in BM clinical tissue
Fitzgerald et al., 2012
Human epidermal growth
factor receptor 2 (HER2)
and vascular endothelial
growth factor receptor 2
(VEGFR2)
anti-VEGFR2 (DC101),
lapatinib and
trastuzumab
BT-474/intracranial decreased
BM/increased
survival
first targeted therapy combination;
treatment study
Kodack et al., 2012
Matrix-metalloproteinase 1
(MMP1)
shRNA MDA-MB- 231-BR
and -BR3/intracardiac
decreased BM also effective in lung
metastasis model
Liu et al., 2012
Phosphatidylinositide
3-kinase (PI3K)
BKM-120 Rag2/;Il2rg/
mice/MDA-MB-453,
BT-474/intravenous and
intramammary
decreased BM spontaneous brain metastasis
model; model further recapitulates
multi-organ metastasis
Nanni et al., 2012
MET proto-oncogene,
receptor tyrosine
kinase (MET)
shRNA MDA-MB-435/intracranial decreased BM survival benefit in intra-internal
carotid artery injection model;
increased expression in BM
clinical tissue
Lee et al., 2013
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1
6
6
C
a
n
c
e
r
C
e
ll2
7
,
F
e
b
ru
a
ry
9
,
2
0
1
5
ª
2
0
1
5
E
ls
e
v
ie
r
In
c
.
C
a
n
c
e
r
C
e
ll
P
e
rs
p
e
c
tiv
e
Table 1. Continued
Targeta Targeting Methodb Modelc Outcome Commentsd References
Neurotrophin 3 (NT3) shRNA MDA-MB-361/intracranial decreased BM NT3 expression decreases microglia
activation and increases HER2
expression; increased expression
in BM clinical tissue
Louie et al., 2013
Chemotherapy HA–paclitaxel
nanoconjugate
MDA-MB-231-BR/intracardiac increased survival HA conjugate increases delivery
of paclitaxel into the brain by
bypassing p-glycoprotein
mediated efflux
Mittapalli et al., 2013
Epidermal growth factor
receptors 1 and 2 (EGFR
and HER2)
TAK-285 (dual EGFR
and HER2 inhibitor)
BT-474/intracranial decreased BM TAK-285 evades efflux mechanism
since not a p-glycoprotein
substrate; treatment study
Nakayama et al., 2013
Bone morphogenetic
protein 2 (BMP2)
shRNA MDA-MB-231BR/intracranial decreased BM BMP2 promotes differentiation
of NPCs into astrocytes;
expressed in BM clinical tissue
Neman et al., 2013
Kruppel-like
factor 4 (KLF4)
miR-7 CD24_CD44+_ESA+ CSCs
from 231BrM/intracardiac
decreased
BM/increased
survival
high KLF4 expression is inversely
correlated with brain metastasis-free
survival; miR-7 is
downregulated and KLF4
upregulated in BM clinical tissue
Okuda et al., 2013
Insulin-like growth
factor 1 receptor (IGF-1R)
shRNA MDA-MB-231BR/intracarotid increased survival picropodophyllin used to block
IGF-IR in vitro but not in vivo
Saldana et al., 2013
SRC proto-oncogene,
non-receptor tyrosine
kinase (SRC)
saracatinib
with lapatinib
BT-474-BR and
MDA-MB-231-BR/intracarotid
decreased BM and
increased survival
monotherapy does not significantly
decrease BM; effective on
established BM; increased
expression in BM clinical tissue;
treatment study
Zhang et al., 2013
Angiopoietin 2 (Ang-2) trebananib 4T1-BRM5 murine mammary
carcinoma cells/mammary
fat pad
decreased BM spontaneous brain metastasis;
trebananib improves BBB integrity;
Ang-2 is secreted by endothelial
cells
Avraham et al., 2014
Fructose-1,6-bisphosphatase
(FBP)
shRNA 4T1 murine mammary
carcinoma cells/intracarotid
decreased
BM/increased
survival
knockdown of FBP2 does not
reduce primary tumor growth;
highlights microenvironment-specific
regulation of tumor metabolism;
FBP-2 expressed in BM clinical
tissue
Chen et al., 2014
aB-crystallin shRNA GILM2/intramammary decreased BM spontaneous brain metastasis
model; aB-crystallin knockdown
does not reduce primary tumor
growth; increased expression in
BM clinical tissue
Malin et al., 2014
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Cancer Cell
PerspectiveDespite major preclinical advances, the clinical role of prophy-
lactic approaches for BCBM is poorly investigated, and clinical
features alonemay not identify high-risk patients for BM to justify
the toxicity associated with prophylactic therapies. The identifi-
cation of tissue-based risk signatures could help overcome
this dilemma. Prophylactic cranial irradiation (PCI) slowed dis-
ease progression resulting in survival benefit in small-cell lung
cancer (SCLC), providing the rationale for application in breast
cancer. Currently, a randomized phase III trial is investigating
the potential of a prophylactic taxane/trastuzumab treatment
alone or in combination with PCI (Table 2). Published case series
and retrospective analyses, however, indicate that PCI and its
benefit-to-risk ratio in breast cancer patients at high risk for
BM should be approached critically (Huang et al., 2009). A phase
III trial comparing the EGFR/HER2 kinase inhibitor lapatinib plus
capecitabine versus capecitabine alone in patients with locally
advanced or metastatic HER2-positive breast cancer that
were previously treated with taxane-, anthracycline-, or trastuzu-
mab-containing therapies revealed a significant reduction in the
number of cases with CNS involvement as the first site of pro-
gression. These results indicate that the addition of the receptor
tyrosine kinase (RTK) inhibitor to chemotherapy can improve the
prevention of brain metastases (Cameron et al., 2008). In agree-
ment with the efficacy of this combination on preventing brain
lesions, significant responses were witnessed in patients with
established disease (Bachelot et al., 2013).
BM can be diagnosed many years after the initial diagnosis of
breast cancer. This should be taken into consideration when
investigating the role of prophylactic therapies. Recent studies
revealed that single cells or clusters of disseminated breast can-
cer cells might remain quiescent for a long time. This latency can
be induced by endothelial-derived thrombospondin-1, suggest-
ing the perivascular niche can regulate breast tumor dormancy
(Ghajar et al., 2013). The dormancy of disseminated breast can-
cer cells depends on the histologic subtype (Aversa et al., 2014)
and poses a major challenge for prophylactic strategies, which
may cause severe adverse effects. For example, cranial irradia-
tion is associated with acute, subacute, and late/chronic toxicity.
In the acute phase, radiation therapy can cause vasogenic
edema, resulting in headache, nausea, or neurologic deficits.
Subacute encephalopathy may appear up to 6 months post-
treatment and can progress into chronic cerebral dysfunction.
The latter can be irreversible and cause neurocognitive deficits,
leukoencephalopathy, cerebral atrophy, or even radiation-
induced necrosis (Dietrich et al., 2008; Le Pe´choux et al.,
2011). Markers for neuronal injury can be detected in the cere-
brospinal fluid (CSF) of patients after PCI, despite the moderate
radiation doses used (Kalm et al., 2014). Similarly, RTKs such as
lapatinib can induce significant toxicities, including cutaneous,
gastrointestinal, and hematologic side effects, as well as fatigue
(Crown et al., 2013). The long latency of BM makes the determi-
nation of the optimal time point for treatment initiation difficult. All
of these factors must be taken into account when designing pro-
phylactic clinical trials.
Is the Brain Microenvironment the Achilles’ Heel of
Modern Therapies?
The anti-HER2 antibody trastuzumab, one of the most widely
prescribed targeted therapeutics, is an essential component in
Table 2. Ongoing Clinical Trials in Patients with BCBM
Population Phase Primary Endpoint Status Clinicaltrials.gov ID
PREVENTION
PCI HER2-positive I safety, neurocognitive function completed NCT00916877
PCI HER2-positive III incidence of BM in women
receiving trastuzumab and
chemotherapy
completed NCT00639366
Lapatinib + capecitabine HER2-positive III CNS metastasis as site of
first relapse
active NCT00820222
TREATMENT
Trastuzumab + BKM120 HER2-positive I adverse events and DLT active NCT01132664
Trastuzumab + everolimus + vinorelbine HER2-positive II intracranial ORR recruiting NCT01305941
Trastuzumab + ARRY-380 HER2-positive I maximum tolerated dose of
ARRY-380 with trastuzumab
recruiting NCT01921335
Trastuzumab + GRN1005 HER2-positive II intracranial ORR recruiting NCT01480583
Lapatinib HER2-positive II CNS ORR completed NCT00098605
Lapatinib + WBRT breast and lung
cancer brain
metastases
II response rate recruiting NCT01218529
Lapatinib + WBRT HER2-positive II response recruiting NCT01622868
Lapatinib + temozolomide HER2-positive I MTD and DLT completed NCT00614978
Lapatinib + WBRT HER2-positive I MTD completed NCT00470847
Lapatinib + capecitabine HER2-positive II ORR completed NCT00967031
Afatinib ± vinorelbine HER2-positive II benefit at 12 weeks completed NCT01441596
Neratinib HER2-positive II ORR recruiting NCT01494662
Bevacizumab + carboplatin all subtypes II CNS ORR active NCT01004172
Bevacizumab + cisplatin + etoposide all subtypes II ORR completed NCT01281696
ANG1005 HER2-positive II intracranial ORR recruiting NCT02048059
INIPARIB + irinotecan triple-negative II efficacy as measured by
intra or extracranial TTP
completed NCT01173497
BKM120 + capecitabine triple-negative II clinical benefit rate recruiting NCT02000882
Stereotactic radiotherapy + HER2
therapy
HER2-positive II 6-month distant brain
relapse rate
not yet open
for recruitment
NCT01924351
Hippocampus-sparing WBRT all subtypes III cognitive toxicity recruiting NCT01942980
Bevacizumab + etoposide + cisplatin
followed by WBRT
all subtypes II brain-specific PFS not yet open
for recruitment
NCT02185352
WBRT + temozolomide breast and lung
cancer brain
metastases
II ORR not yet open
for recruitment
NCT02133677
Lapatinib following cranial radiotherapy HER2-positive II response to lapatinib ongoing NCT00263588
WBRT + sorafenib all subtypes I MTD recruiting NCT01724606
Cabozantinib ± trastuzumab all subtypes II ORR not yet open
for recruitment
NCT02260531
Ado-trastuzumab emtansine + radiotherapy HER2-positive I optimal sequence ongoing NCT02135159
Abemaciclib hormone
receptor
positive
II ORR not yet open
for recruitment
NCT02308020
Capecitabine + radiotherapy all subtypes II best objective CNS response completed NCT00977379
Cabazitaxel breast cancer
and lung cancer
II objective tumor response not yet open
for recruitment
NCT02166658
KD019 + trastuzumab HER2 positive Ib/IIa safety/tolerability recruiting NCT02154529
Epothilone B all subtypes II CNS PFS completed NCT00450866
TPI 287 all subtypes II ORR recruiting NCT01332630
PCI, prophylactic cranial irradiation; WBRT, whole brain radiotherapy; BM, brain metastases; MTD, maximum tolerated dose; DLT, dose-limiting
toxicity; TTP, time to progression; PFS, progression-free survival; ORR, overall response rate.
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Cancer Cell
Perspectivethe treatment of HER2-positive breast cancer. Although trastu-
zumab is effective for systemic disease, its efficacy against
BM remains controversial. Differential sensitivity to trastuzumab
between BM and mammary fat pad tumors is unambiguous (Ko-
dack et al., 2012). Meta-analysis of the phase III adjuvant trials
NSABP B31, NCCTG N9831, HERA, and PACS 04 revealed a
higher incidence for cerebral metastasis after adjuvant treatment
with trastuzumab (Olson et al., 2013). This is associated with
controlled systemic, extracranial disease (Bendell et al., 2003),
supporting the hypothesis that the enhanced risk for BM after
adjuvant trastuzumab treatment is due to improved systemic
control. Clinical evidence for the efficacy of trastuzumab against
established BM is limited, mainly due to the lack of prospective
data in this setting. Retrospective analyses indicate a trend to-
ward improved outcome (Bartsch et al., 2007); however, it re-
mains unclear whether the benefit is due to improved systemic
control or drug efficacy against the cerebral lesions. In either
case, the relative risk of the brain as the first site of relapse is
significantly increased in HER2-positive patients treated with
trastuzumab (Olson et al., 2013).
The limited efficacy of trastuzumab against BM is often attrib-
uted to an inadequate penetration through the BBB. Based on its
presumed ability to better penetrate the BBB than trastuzumab,
lapatinib, a small-molecule kinase inhibitor of EGFR and HER2,
was evaluated in BCBM. Lapatinib exhibited efficacy in a preclin-
ical prevention model of HER2-overexpressing BCBM (Gril et al.,
2008), leading to prospective clinical trials. In breast cancer pa-
tients with HER2-positive BM that progressed after WBRT, lapa-
tinib showed very modest activity as a single agent (Lin et al.,
2008, 2009). In one study of 39 patients, there was only one par-
tial response (2.6%) at 16 weeks after lapatinib initiation; mean-
while, 4 of 16 patients (25%) with non-CNS disease achieved a
partial response but were eventually taken off due to CNS pro-
gression (Lin et al., 2008). In a separate study, lapatinib mono-
therapy showed a response rate of 6% (15 of 237) in a similar
subset of patients (Lin et al., 2009). The success of lapatinib
and capecitabine for systemic disease along with its activity in
preventing brain metastasis led to its inclusion in patients with
established BM. Interestingly, the addition of capecitabine to
lapatinib increased response rates to 20% (Lin et al., 2009).
Consistent with this data, the combination of lapatinib and cape-
citabine, before WBRT, in newly diagnosed BM (LANDSCAPE
trial) revealed a CNS objective response rate of 67% (Bachelot
et al., 2013). Further analysis indicated that the response corre-
lated with a decrease in CTCs during treatment (Pierga et al.,
2013). The mechanism for the significant efficacy of the combi-
nation treatment regimen remains unclear, but clearly capecita-
bine is active in this setting. As with trastuzumab, the question of
whether brain metastatic resistance to lapatinib monotherapy is
due in part to a lack of drug penetration remains unresolved, as
this parameter has not been thoroughly investigated in the clin-
ical setting.
Blood-Brain Barrier: Time to Rethink Its Importance in
Treating BM?
The BBB and expression of BBB transporters are thought to
diminish the concentration of systemic therapy available to brain
metastatic lesions (Deeken and Lo¨scher, 2007). However, the
blood-tumor barrier (BTB) is leakier than the BBB and permits170 Cancer Cell 27, February 9, 2015 ª2015 Elsevier Inc.delivery in brain lesions especially at later stages of disease
(Murrell et al., 2014). The extent of BBB disruption varies among
tumor subtypes (Yonemori et al., 2010). Consistent with a disrup-
ted BBB, significant responses to chemotherapy are reported.
Rosner et al. (1986) found a brain-specific objective response
rate of 50% in 100 breast cancer patients with symptomatic
BM treated with a variety of chemotherapies. These findings
were supported in subsequent studies (Stemmler and Heine-
mann, 2008) and include activity of capecitabine monotherapy,
which was shown to achieve clinically relevant concentrations
in nonirradiated human BCBM (Morikawa et al., 2013). Despite
these reports suggesting a direct activity of chemotherapy in
BM similar to what is observed in extracranial disease, chemo-
therapy is generally prescribed secondary to surgery or radio-
therapy.
Diminished CSF concentration, compared to plasma levels,
was cited as a mechanism of trastuzumab ineffectiveness due
to an inadequate penetration through the BBB (Stemmler et al.,
2007). However, the CSF represents a separate compartment
from the brain parenchyma, separated from the parenteral circu-
lation by the blood-CSF barrier and from the brain parenchyma
by the glia limitans. In support of inadequate trastuzumab pene-
tration as a reason for its ineffectiveness, increased delivery of
trastuzumab via phosphodiesterase inhibition-induced BBB
disruption enhanced its efficacy in a murine intracranial model
(Hu et al., 2010). Consistent with the BTB being leaky, PET-
based clinical studies demonstrated an accumulation of trastu-
zumab in human BCBM despite its high molecular weight
(Tamura et al., 2013). It remains unclear, however, whether the
concentration of trastuzumab achieved in the BM setting is suf-
ficient to slow tumor growth (Lampson, 2011). Recent clinical
findings describing the efficacy of antibody-based therapy in
BCBM suggest sufficient concentrations are achieved in brain
metastatic lesions—these include bevacizumab (N.U. Lin et al.,
2013, Am. Soc. Clin. Oncol., abstract 513; Y.S. Lu et al., 2012,
Am. Soc. Clin. Oncol., abstract 1079) and trastuzumab-DM1
(Bartsch et al., 2014; Krop et al., 2014; Yamamoto et al., 2012)
(see ‘‘Targeting the BrainMicroenvironment for Successful Ther-
apy’’ and ‘‘Future Approaches’’). As with trastuzumab, the ques-
tion of achieving an adequate concentration of lapatinib within
the BM lesion remains unanswered. In preclinical models, lapa-
tinib accumulated in brain lesions at higher concentrations than
the normal brain, but at significantly lower levels than extracra-
nial disease (Kodack et al., 2012; Taskar et al., 2012). Still, the
concentrations achieved were significantly higher than its IC50
in vitro, and in our study led to significant inhibition of HER2
phosphorylation and downstream signaling. Human data indi-
cate clinically relevant lapatinib concentrations are achieved in
a number of BCBM, though a significant variation among them
exists (Morikawa et al., 2013).
Strategies to enhance the delivery of therapeutics into the
CNS have been actively pursued and are beginning to undergo
clinical evaluation. Radiation is known to disrupt the BBB (Brown
et al., 2005). Hence, the efficacy of trastuzumab, lapatinib, and/
or bevacizumab in combination with radiotherapy is currently be-
ing investigated in clinical trials (see Table 2). Other approaches
to physically break down the BBB include infusion of a hyperos-
motic agent, focused ultrasound, or treatment with bradykinin
analogs (Eichler et al., 2011). One concern about disruption of
Cancer Cell
Perspectivethe BBB is the potential of allowing circulating cancer cells more
ready access to the brain parenchyma, thus potentially initiating
new brain lesions. Furthermore, chronic BBB breakdown is
associated with the accumulation of serum proteins and periph-
erally derived neurotoxic macromolecules, ultimately leading to
neuronal degenerative changes (Bell et al., 2010). In addition to
BBB disruption, other methods have been studied to enhance
drug movement across the BBB. Taking advantage of the
endogenously expressed BBB receptor low-density lipoprotein
receptor-related protein (LRP-1), peptide-chemotherapy conju-
gates were designed to achieve superior delivery into preclinical
brain metastasis models (Thomas et al., 2009). This class of
agents is currently being tested in phase II clinical trials
(NCT01480583 and NCT02048059; Table 2). Other receptors
that have been exploited for receptor-mediated BBB transcyto-
sis include the transferrin, insulin, and insulin-like growth factor-1
receptors (Eichler et al., 2011).
Another issue that remains clinically unexplored is whether
active drug efflux mechanisms compromise the delivery of ther-
apeutics in BM. While preclinical data indicate that P-glycopro-
tein (P-gp)-mediated efflux kinetics are similar between normal
BBB and BTB (Adkins et al., 2013), clinical data suggest P-gp
expression in metastatic brain tumors is similar to that of primary
extracranial tumors and decreased compared to primary brain
tumors (Gerstner and Fine, 2007). In a murine model, a non-
P-gp substrate HER2/EGFR kinase inhibitor displayed modest
but significantly better control of brain tumors compared with la-
patinib (Nakayama et al., 2013), supporting the role of active drug
efflux on pharmacokinetics and efficacy. While inhibitors of P-gp
and other BBB transporters have increased drug concentrations
in the murine CNS, knowledge of their efficacy on tumor growth
of BCBM is lacking.
Targeting the Brain Microenvironment for Successful
Therapy
In preclinical models, BM from breast cancer exhibit higher
microvascular density than their respective primary tumors
(Monsky et al., 2002). These data underscore the crucial role of
the microenvironment in shaping and defining biological proper-
ties of the tumor and suggest that BM may be more reliant on
blood vessels than primary tumors. Indeed, angiogenesis is
required for efficient colonization and growth of breast cancer
cells in the brain, as inhibiting vascular endothelial growth factor
(VEGF) receptor activation reduces brain metastatic growth of
brain-tropic breast cancer cell variants through a reduction in
angiogenesis (Kim et al., 2004). Despite the lack of an overall
survival benefit with the anti-VEGF antibody bevacizumab (in
combination with chemotherapy) in breast cancer patients with
extracranial disease (Brufsky et al., 2011a; Robert et al., 2011),
case series suggest that patients with BM may benefit from the
addition of bevacizumab to systemic chemotherapy (Yamamoto
et al., 2012). Furthermore, preliminary data from phase II clinical
trials show objective response rates of up to 75% with the com-
bination of bevacizumab and chemotherapy (N.U. Lin et al.,
2013, Am. Soc. Clin. Oncol., abstract 513; Y.S. Lu et al., 2012,
Am. Soc. Clin. Oncol., abstract 1079). This is the subject of inves-
tigation in an ongoing clinical trial in BCBM patients (www.
clinicaltrials.gov identifier NCT01004172; Table 2). These find-
ings raise the questions of whether BM aremore reliant on angio-genesis than extracranial tumors and/or if the brain endothelium
is more reliant on VEGF than the systemic vasculature. While we
hypothesize the increased vascularity of BM is due to enhanced
angiogenesis, it could also result from vessel co-option, a known
mechanism of resistance to anti-VEGF therapies in primary brain
tumors (di Tomaso et al., 2011; Jain, 2014). We will be better
positioned to answer these questions as findings from the clin-
ical trials become available.
The crosstalk between the HER2 and VEGF pathways pro-
vides a compelling rationale for combined approaches with
HER2-targeted agents and anti-VEGF drugs. Despite the lack
of a progression-free survival benefit with bevacizumab plus
trastuzumab and docetaxel in patients with HER2-positive
locally recurrent or metastatic extracranial disease (Gianni
et al., 2013), there are reasons to be optimistic for this combina-
tion in the setting of BM. The combination of trastuzumab or
lapatinib with antibodies targeting VEGF receptor-2 was very
effective in preclinical BCBM models (Kodack et al., 2012), and
preliminary analysis of a phase II clinical trial of bevacizumab,
trastuzumab, and carboplatin shows objective response rates
of up to 75% (N.U. Lin et al., 2013, Am. Soc. Clin. Oncol., ab-
stract 513; Y.S. Lu et al., 2012, Am. Soc. Clin. Oncol., abstract
1079). This study is currently ongoing (NCT01004172; see
Table 2) and will determine if a phase III trial is warranted.
Furthermore, the combination of anti-VEGF therapy and dual
HER2 inhibition (trastuzumab plus lapatinib) showed the best
activity in preclinical models and is well tolerated and active in
heavily pretreated patients, including those with brain lesions
(Falchook et al., 2013; Kodack et al., 2012).
Our studies have also shown that trastuzumab can induce
vessel normalization in preclinical models of HER2 overexpress-
ing BCBM (Izumi et al., 2002), a feature that is associated
with improved tumor oxygenation and radiosensitization (Win-
kler et al., 2004). This finding provides a rationale to combine
trastuzumab with radiotherapy.
Future Approaches for Treating BCBM
Additional approaches focus on the use of novel targeting agents
for BCBM. Recently the novel antibody-chemotherapy conju-
gate ado-trastuzumab emtansine (T-DM1) was approved for
the treatment of HER2-positive breast cancer. Approval was
based on the prospective phase III trial EMILIA, which revealed
that T-DM1 was superior to lapatinib and capecitabine in pa-
tients with disease progression after trastuzumab (Verma et al.,
2012). If reduced efficacy of trastuzumab in BM is not due solely
to inefficient delivery, but instead due to acquired or microenvi-
ronment-mediated activation of alternative signaling pathways,
T-DM1 would be expected to be effective in these patients.
This hypothesis is supported by preclinical findings (unpublished
data), case reports (Bartsch et al., 2014), and a subgroup anal-
ysis (asymptomatic brain metastases) in a randomized, open-la-
bel, phase III trial of previously treated (physician’s choice) met-
astatic HER2-positive patients (Krop et al., 2014). Furthermore,
new-generation ErbB family inhibitors, more potent and specific
than lapatinib (neratinib and afatinib), showed significant re-
sponses in single cases of BCBM (Yap et al., 2010). Prospective
clinical trials (NCT01494662 and NCT01441596) investigating
the efficacy of these drugs in patients with BCBM are currently
accruing (or recently completed and awaiting results seeCancer Cell 27, February 9, 2015 ª2015 Elsevier Inc. 171
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acquired resistance to anti-HER2 therapy in systemic disease
led to the evaluation of downstream HER2 signaling inhibitors
in BM, including the PI3K inhibitor BKM120 and the mTOR inhib-
itor everolimus, either alone or in combination with trastuzumab
(see Table 2). Furthermore, the HER2 family member HER3, crit-
ical for HER2 downstream signaling, is enriched in human BM
compared to matched primary breast tumors (Da Silva et al.,
2010). Indeed, inhibiting HER3 activity enhances the efficacy of
HER2-targeted therapies in preclinical models of BCBM (unpub-
lished data). The role of immunotherapy in cancer treatment is a
subject of major interest in recent years, but not much is known
with regard to BCBM. Knowledge from other malignancies, such
as the activity of ipilimumab in patients with cerebral metastases
from malignant melanoma (Margolin et al., 2012), suggests that
immune system modulation might be of promise and empha-
sizes the necessity for studies in this direction. Brain metastatic
lesions from breast cancer contain activated microglia, and,
although the brain is considered immune privileged, preclinical
studies clearly showed that the peripheral immune system en-
ters the brain parenchyma after CNS insult (Ousman and Kubes,
2012). Indirect activation of natural killer cells, CD4+ and CD8+
T cells, through CpG oligodeoxynucleotide treatment, prevented
brain metastasis of murine breast carcinoma cells injected into
syngeneic mice but failed to slow the growth of established
BM (Xiong et al., 2008).
Conclusions
Better therapies for BCBM are needed. The efficacy of existing
therapies, used for the treatment of systemic disease, is largely
unclear in patients with BM, mainly due to the fact that the pres-
ence of symptomatic BM served as an exclusion criterion for
most prospective trials, including the phase III studies TH3RESA,
CLEOPATRA, and EMILIA. Therefore, to better understand the
efficacy of standard targeted therapies, patients with BM must
be included in clinical trials. Furthermore, analysis of clinical tis-
sue to confirm preclinical data and determine clinical evidence of
suspected resistancemechanisms is necessary. While a number
of preclinical reports identify genes that mediate BM, most
describe those necessary for the initial steps of brain metastatic
colonization. This provides essential information and rationale
for clinical applications on metastasis prevention; however, the
central issue of effective treatment of established BM remains
open. In this respect there are unanswered questions that
need to be addressed: Is treatment resistance of BM due to a
lack of drug penetration into the brain lesion? Has the brain met-
astatic cancer cell evolved to evade the same therapy to which
its predecessors are sensitive? Does the brain microenviron-
ment provide factors that enable cancer cells to become resis-
tant, and if so, what are these crucial determinants of resistance?
What is the role of intratumoral heterogeneity? How can micro-
environment-targeted therapies, such as antiangiogenic or
immunotherapy, improve the therapeutic efficacy?
Despite the lack of definitive answers to these questions,
recent data provide some insight that could drive future ap-
proaches. The reduced efficacy of antibody-based therapies
in the brain has been attributed to the decreased permeability
through the BBB; however, the efficacy of bevacizumab or
T-DM1 suggests adequate penetration of antibodies into the172 Cancer Cell 27, February 9, 2015 ª2015 Elsevier Inc.brain metastatic lesion and encourages the investigation of
other large molecule therapies in the BM setting. If therapies
are indeed achieving adequate concentrations within BM, then
resistance could be attributed to nonpharmacokinetic mecha-
nisms. Specific features of the brain microenvironment and cur-
rent biological aspects of the seed and soil hypothesis have
been implicated in treatment resistance. This seems, however,
not to be a universal phenomenon but instead may be depen-
dent on the nature of the parental lesion. Whereas the majority
of HER2-positive BCBM are resistant to targeted therapies, the
response rates of lung cancer or melanoma BM to EGFR or
BRAF inhibitors, respectively, are similar to extracranial disease
(Lombardi et al., 2014). This suggests a unique crosstalk be-
tween the brain microenvironment and biological features of
breast cancer cells that need to be investigated in further detail.
Successful therapies may consist of combinatorial approaches
targeting the tumor stroma in addition to the cancer cell, while
limiting neuronal damage. Finally, intratumoral heterogeneity
should be taken into account. Discordance between primary
disease and metastatic lesions has been described (Niikura
et al., 2012). This heterogeneity makes the interactions between
tumor cells and the microenvironment more complicated and
emphasizes the need to select an appropriate therapeutic strat-
egy based on characteristics of the metastases rather than the
primary tumor. In conclusion, despite major preclinical and clin-
ical progress in the characterization, prevention, and manage-
ment of BM, the multitude and complexity of the remaining
questions to be answered will require a tighter integration be-
tween bench and bedside.AUTHOR CONTRIBUTIONS
D.P.K., V.A., G.B.F., D.F., and R.K.J. contributed to the concept, writing, and
editing of the manuscript, tables, and figure.ACKNOWLEDGMENTS
We thank M. Badeaux, S. Goel, A. Batista, D. Duda, and A. Eichler for their
helpful suggestions and editing. This work was supported by US Department
of Defense Breast Cancer Research Innovator Award W81XWH-10-1-0016 (to
R.K.J.); US National Cancer Institute Grants R01-CA126642 (to R.K.J.), P01-
CA080124 (to R.K.J. and D.F.), and R01-CA096915 (to D.F.); Federal Share
Proton Beam Program Income (to R.K.J.); and German Research Foundation
Grant (Deutsche Forschungsgemeinschaft, DFG) AS 422-2/1 (to V.A.). R.K.J.
received consultant fees from Enlight, Ophthotech, and SynDevRx. R.K.J.
owns equity in Enlight, Ophthotech, SynDevRx, and XTuit, and serves on the
Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare
Investors, Tekla Life Sciences Investors, and the Tekla Healthcare Opportu-
nities Fund.
REFERENCES
Adkins, C.E., Mittapalli, R.K., Manda, V.K., Nounou, M.I., Mohammad, A.S.,
Terrell, T.B., Bohn, K.A., Yasemin, C., Grothe, T.R., Lockman, J.A., and
Lockman, P.R. (2013). P-glycoprotein mediated efflux limits substrate and
drug uptake in a preclinical brain metastases of breast cancer model. Front.
Pharmacol. 4, 136.
Armulik, A., Genove´, G., and Betsholtz, C. (2011). Pericytes: developmental,
physiological, and pathological perspectives, problems, and promises. Dev.
Cell 21, 193–215.
Aversa, C., Rossi, V., Geuna, E., Martinello, R., Milani, A., Redana, S., Valab-
rega, G., Aglietta, M., and Montemurro, F. (2014). Metastatic breast cancer
subtypes and central nervous system metastases. Breast 23, 623–628.
Cancer Cell
PerspectiveAvraham, H.K., Jiang, S., Fu, Y., Nakshatri, H., Ovadia, H., and Avraham, S.
(2014). Angiopoietin-2 mediates blood-brain barrier impairment and coloniza-
tion of triple-negative breast cancer cells in brain. J. Pathol. 232, 369–381.
Bachelot, T., Romieu, G., Campone, M., Die´ras, V., Cropet, C., Dalenc, F.,
Jimenez, M., Le Rhun, E., Pierga, J.Y., Gonc¸alves, A., et al. (2013). Lapatinib
plus capecitabine in patients with previously untreated brain metastases
from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group
phase 2 study. Lancet Oncol. 14, 64–71.
Bartsch, R., Rottenfusser, A., Wenzel, C., Dieckmann, K., Pluschnig, U.,
Altorjai, G., Rudas, M., Mader, R.M., Poetter, R., Zielinski, C.C., and Steger,
G.G. (2007). Trastuzumab prolongs overall survival in patients with brain me-
tastases from Her2 positive breast cancer. J. Neurooncol. 85, 311–317.
Bartsch, R., Berghoff, A.S., and Preusser, M. (2014). Breast cancer brain me-
tastases responding to primary systemic therapy with T-DM1. J. Neurooncol.
116, 205–206.
Baschnagel, A., Russo, A., Burgan, W.E., Carter, D., Beam, K., Palmieri, D.,
Steeg, P.S., Tofilon, P., and Camphausen, K. (2009). Vorinostat enhances
the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro
and as intracranial xenografts. Mol. Cancer Ther. 8, 1589–1595.
Bell, R.D., Winkler, E.A., Sagare, A.P., Singh, I., LaRue, B., Deane, R., and Zlo-
kovic, B.V. (2010). Pericytes control key neurovascular functions and neuronal
phenotype in the adult brain and during brain aging. Neuron 68, 409–427.
Bendell, J.C., Domchek, S.M., Burstein, H.J., Harris, L., Younger, J., Kuter, I.,
Bunnell, C., Rue, M., Gelman, R., andWiner, E. (2003). Central nervous system
metastases in women who receive trastuzumab-based therapy for metastatic
breast carcinoma. Cancer 97, 2972–2977.
Bos, P.D., Zhang, X.H., Nadal, C., Shu, W., Gomis, R.R., Nguyen, D.X., Minn,
A.J., van de Vijver, M.J., Gerald, W.L., Foekens, J.A., andMassague, J. (2009).
Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005–
1009.
Brown, W.R., Thore, C.R., Moody, D.M., Robbins, M.E., and Wheeler, K.T.
(2005). Vascular damage after fractionated whole-brain irradiation in rats.
Radiat. Res. 164, 662–668.
Brufsky, A.M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O’Neill, V., and
Rugo, H.S. (2011a). RIBBON-2: a randomized, double-blind, placebo-
controlled, phase III trial evaluating the efficacy and safety of bevacizumab
in combination with chemotherapy for second-line treatment of human
epidermal growth factor receptor 2-negative metastatic breast cancer.
J. Clin. Oncol. 29, 4286–4293.
Brufsky, A.M., Mayer, M., Rugo, H.S., Kaufman, P.A., Tan-Chiu, E., Tripathy,
D., Tudor, I.C., Wang, L.I., Brammer, M.G., Shing, M., et al. (2011b). Central
nervous system metastases in patients with HER2-positive metastatic breast
cancer: incidence, treatment, and survival in patients from registHER. Clin.
Cancer Res. 17, 4834–4843.
Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu,
C.G., Chan, S., Jagiello-Gruszfeld, A., Kaufman, B., Crown, J., et al. (2008).
A phase III randomized comparison of lapatinib plus capecitabine versus ca-
pecitabine alone in women with advanced breast cancer that has progressed
on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer
Res. Treat. 112, 533–543.
Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu,
L.R., Gao, G., et al. (2014). Gain of glucose-independent growth upon metas-
tasis of breast cancer cells to the brain. Cancer Res. 75, 1–12.
Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J.K., Fang, X., Sloan,
A.E., Mao, Y., Lathia, J.D., et al. (2013). Glioblastoma stem cells generate
vascular pericytes to support vessel function and tumor growth. Cell 153,
139–152.
Chiu, W.T., Lee, H.T., Huang, F.J., Aldape, K.D., Yao, J., Steeg, P.S., Chou,
C.Y., Lu, Z., Xie, K., and Huang, S. (2011). Caveolin-1 upregulation mediates
suppression of primary breast tumor growth and brain metastases by stat3
inhibition. Cancer Res. 71, 4932–4943.
Crown, J., Kennedy, M.J., Tresca, P., Marty, M., Espie, M., Burris, H.A.,
DeSilvio, M., Lau, M.R., Kothari, D., Koch, K.M., and Die´ras, V. (2013). Opti-
mally tolerated dose of lapatinib in combination with docetaxel plus trastuzu-
mab in first-line treatment of HER2-positive metastatic breast cancer. Ann.
Oncol. 24, 2005–2011.Da Silva, L., Simpson, P.T., Smart, C.E., Cocciardi, S., Waddell, N., Lane, A.,
Morrison, B.J., Vargas, A.C., Healey, S., Beesley, J., et al. (2010). HER3 and
downstream pathways are involved in colonization of brain metastases from
breast cancer. Breast Cancer Res. 12, R46.
Deeken, J.F., and Lo¨scher, W. (2007). The blood-brain barrier and cancer:
transporters, treatment, and Trojan horses. Clin. Cancer Res. 13, 1663–1674.
di Tomaso, E., Snuderl, M., Kamoun, W.S., Duda, D.G., Auluck, P.K., Fazlol-
lahi, L., Andronesi, O.C., Frosch, M.P., Wen, P.Y., Plotkin, S.R., et al. (2011).
Glioblastoma recurrence after cediranib therapy in patients: lack of ‘‘rebound’’
revascularization as mode of escape. Cancer Res. 71, 19–28.
Dietrich, J., Monje, M., Wefel, J., and Meyers, C. (2008). Clinical patterns and
biological correlates of cognitive dysfunction associated with cancer therapy.
Oncologist 13, 1285–1295.
Duda, D.G., Duyverman, A.M., Kohno, M., Snuderl, M., Steller, E.J., Fukumura,
D., and Jain, R.K. (2010). Malignant cells facilitate lung metastasis by bringing
their own soil. Proc. Natl. Acad. Sci. USA 107, 21677–21682.
Eichler, A.F., Chung, E., Kodack, D.P., Loeffler, J.S., Fukumura, D., and Jain,
R.K. (2011). The biology of brain metastases-translation to new therapies. Nat.
Rev. Clin. Oncol. 8, 344–356.
Falchook, G.S., Moulder, S.L., Wheler, J.J., Jiang, Y., Bastida, C.C., and Kurz-
rock, R. (2013). Dual HER2 inhibition in combination with anti-VEGF treatment
is active in heavily pretreated HER2-positive breast cancer. Ann. Oncol. 24,
3004–3011.
Fitzgerald, D.P., Palmieri, D., Hua, E., Hargrave, E., Herring, J.M., Qian, Y.,
Vega-Valle, E., Weil, R.J., Stark, A.M., Vortmeyer, A.O., and Steeg, P.S.
(2008). Reactive glia are recruited by highly proliferative brain metastases of
breast cancer and promote tumor cell colonization. Clin. Exp. Metastasis 25,
799–810.
Fitzgerald, D.P., Subramanian, P., Deshpande, M., Graves, C., Gordon, I.,
Qian, Y., Snitkovsky, Y., Liewehr, D.J., Steinberg, S.M., Palta´n-Ortiz, J.D.,
et al. (2012). Opposing effects of pigment epithelium-derived factor on breast
cancer cell versus neuronal survival: implication for brain metastasis and
metastasis-induced brain damage. Cancer Res. 72, 144–153.
Gerstner, E.R., and Fine, R.L. (2007). Increased permeability of the blood-brain
barrier to chemotherapy in metastatic brain tumors: establishing a treatment
paradigm. J. Clin. Oncol. 25, 2306–2312.
Ghajar, C.M., Peinado, H., Mori, H., Matei, I.R., Evason, K.J., Brazier, H.,
Almeida, D., Koller, A., Hajjar, K.A., Stainier, D.Y., et al. (2013). The perivascular
niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807–817.
Gianni, L., Romieu, G.H., Lichinitser, M., Serrano, S.V., Mansutti, M., Pivot, X.,
Mariani, P., Andre, F., Chan, A., Lipatov, O., et al. (2013). AVEREL: a random-
ized phase III Trial evaluating bevacizumab in combination with docetaxel and
trastuzumab as first-line therapy for HER2-positive locally recurrent/metasta-
tic breast cancer. J. Clin. Oncol. 31, 1719–1725.
Gori, S., Rimondini, S., De Angelis, V., Colozza, M., Bisagni, G., Moretti, G., Si-
doni, A., Basurto, C., Aristei, C., Anastasi, P., and Crino`, L. (2007). Central ner-
vous system metastases in HER-2 positive metastatic breast cancer patients
treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12,
766–773.
Gril, B., Palmieri, D., Bronder, J.L., Herring, J.M., Vega-Valle, E., Feigenbaum,
L., Liewehr, D.J., Steinberg, S.M., Merino, M.J., Rubin, S.D., and Steeg, P.S.
(2008). Effect of lapatinib on the outgrowth of metastatic breast cancer cells
to the brain. J. Natl. Cancer Inst. 100, 1092–1103.
Gril, B., Palmieri, D., Qian, Y., Smart, D., Ileva, L., Liewehr, D.J., Steinberg,
S.M., and Steeg, P.S. (2011). Pazopanib reveals a role for tumor cell B-Raf
in the prevention of HER2+ breast cancer brain metastasis. Clin. Cancer
Res. 17, 142–153.
Grossi, P.M., Ochiai, H., Archer, G.E., McLendon, R.E., Zalutsky, M.R., Fried-
man, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H. (2003). Efficacy of
intracerebral microinfusion of trastuzumab in an athymic rat model of intrace-
rebral metastatic breast cancer. Clin. Cancer Res. 9, 5514–5520.
Hu, J., Ljubimova, J.Y., Inoue, S., Konda, B., Patil, R., Ding, H., Espinoza, A.,
Wawrowsky, K.A., Patil, C., Ljubimov, A.V., and Black, K.L. (2010). Phospho-
diesterase type 5 inhibitors increase Herceptin transport and treatment effi-
cacy in mouse metastatic brain tumor models. PLoS ONE 5, e10108.Cancer Cell 27, February 9, 2015 ª2015 Elsevier Inc. 173
Cancer Cell
PerspectiveHuang, F., Alrefae, M., Langleben, A., and Roberge, D. (2009). Prophylactic
cranial irradiation in advanced breast cancer: a case for caution. Int. J. Radiat.
Oncol. Biol. Phys. 73, 752–758.
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., and Jain, R.K. (2002). Tumour
biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280.
Jain, R.K. (2014). Antiangiogenesis strategies revisited: from starving tumors
to alleviating hypoxia. Cancer Cell 26, 605–622.
Kalm, M., Abel, E., Wasling, P., Nyman, J., Hietala, M.A., Bremell, D., Hagberg,
L., Elam,M., Blennow, K., Bjo¨rk-Eriksson, T., and Zetterberg, H. (2014). Neuro-
chemical evidence of potential neurotoxicity after prophylactic cranial irradia-
tion. Int. J. Radiat. Oncol. Biol. Phys. 89, 607–614.
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M.C., Voduc, D., Speers,
C.H., Nielsen, T.O., and Gelmon, K. (2010). Metastatic behavior of breast can-
cer subtypes. J. Clin. Oncol. 28, 3271–3277.
Kienast, Y., von Baumgarten, L., Fuhrmann, M., Klinkert, W.E., Goldbrunner,
R., Herms, J., and Winkler, F. (2010). Real-time imaging reveals the single
steps of brain metastasis formation. Nat. Med. 16, 116–122.
Kim, L.S., Huang, S., Lu, W., Lev, D.C., and Price, J.E. (2004). Vascular endo-
thelial growth factor expression promotes the growth of breast cancer brain
metastases in nude mice. Clin. Exp. Metastasis 21, 107–118.
Kim, S.J., Kim, J.S., Park, E.S., Lee, J.S., Lin, Q., Langley, R.R., Maya, M., He,
J., Kim, S.W., Weihua, Z., et al. (2011). Astrocytes upregulate survival genes in
tumor cells and induce protection from chemotherapy. Neoplasia 13, 286–298.
Kim, S.W., Choi, H.J., Lee, H.J., He, J., Wu, Q., Langley, R.R., Fidler, I.J., and
Kim, S.J. (2014). Role of the endothelin axis in astrocyte- and endothelial cell-
mediated chemoprotection of cancer cells. Neuro. Oncol. 16, 1585–1598.
Kocher, M., Soffietti, R., Abacioglu, U., Villa`, S., Fauchon, F., Baumert, B.G.,
Fariselli, L., Tzuk-Shina, T., Kortmann, R.D., Carrie, C., et al. (2011). Adjuvant
whole-brain radiotherapy versus observation after radiosurgery or surgical
resection of one to three cerebral metastases: results of the EORTC 22952-
26001 study. J. Clin. Oncol. 29, 134–141.
Kodack, D.P., Chung, E., Yamashita, H., Incio, J., Duyverman, A.M., Song, Y.,
Farrar, C.T., Huang, Y., Ager, E., Kamoun,W., et al. (2012). Combined targeting
of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer
brain metastases. Proc. Natl. Acad. Sci. USA 109, E3119–E3127.
Krop, I.E., Kim, S.B., Gonza´lez-Martı´n, A., LoRusso, P.M., Ferrero, J.M., Smitt,
M., Yu, R., Leung, A.C., and Wildiers, H.; TH3RESA Study Collaborators
(2014). Trastuzumab emtansine versus treatment of physician’s choice for pre-
treated HER2-positive advanced breast cancer (TH3RESA): a randomised,
open-label, phase 3 trial. Lancet Oncol. 15, 689–699.
Lampson, L.A. (2011). Monoclonal antibodies in neuro-oncology: getting past
the blood-brain barrier. MAbs 3, 153–160.
Le Pe´choux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R.,
Lerouge, D., Keus, R., Hatton, M., Videtic, G.M., Senan, S., et al. (2011). Clin-
ical neurological outcome and quality of life among patients with limited small-
cell cancer treated with two different doses of prophylactic cranial irradiation in
the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and
IFCT 99-01). Ann. Oncol. 22, 1154–1163.
Lee, S.J., Seol, H.J., Lee, H.W., Kang, W.Y., Kang, B.G., Jin, J., Jo, M.Y., Jin,
Y., Lee, J.I., Joo, K.M., and Nam, D.H. (2013). Gene silencing of c-Met leads to
brain metastasis inhibitory effects. Clin. Exp. Metastasis 30, 845–854.
Lin, N.U., Carey, L.A., Liu, M.C., Younger, J., Come, S.E., Ewend, M., Harris,
G.J., Bullitt, E., Van den Abbeele, A.D., Henson, J.W., et al. (2008). Phase II trial
of lapatinib for brain metastases in patients with human epidermal growth
factor receptor 2-positive breast cancer. J. Clin. Oncol. 26, 1993–1999.
Lin, N.U., Die´ras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.J.,
Roche´, H., Liu, M.C., Greil, R., Ciruelos, E., et al. (2009). Multicenter phase II
study of lapatinib in patients with brain metastases from HER2-positive breast
cancer. Clin. Cancer Res. 15, 1452–1459.
Liu, H., Kato, Y., Erzinger, S.A., Kiriakova, G.M., Qian, Y., Palmieri, D., Steeg,
P.S., and Price, J.E. (2012). The role of MMP-1 in breast cancer growth and
metastasis to the brain in a xenograft model. BMC Cancer 12, 583.
Lombardi, G., Di Stefano, A.L., Farina, P., Zagonel, V., and Tabouret, E. (2014).
Systemic treatments for brain metastases from breast cancer, non-small cell174 Cancer Cell 27, February 9, 2015 ª2015 Elsevier Inc.lung cancer, melanoma and renal cell carcinoma: an overview of the literature.
Cancer Treat. Rev. 40, 951–959.
Lorger, M., and Felding-Habermann, B. (2010). Capturing changes in the brain
microenvironment during initial steps of breast cancer brain metastasis. Am. J.
Pathol. 176, 2958–2971.
Lorger, M., Krueger, J.S., O’Neal, M., Staflin, K., and Felding-Habermann, B.
(2009). Activation of tumor cell integrin alphavbeta3 controls angiogenesis
and metastatic growth in the brain. Proc. Natl. Acad. Sci. USA 106, 10666–
10671.
Louie, E., Chen, X.F., Coomes, A., Ji, K., Tsirka, S., and Chen, E.I. (2013). Neu-
rotrophin-3 modulates breast cancer cells and the microenvironment to pro-
mote the growth of breast cancer brain metastasis. Oncogene 32, 4064–4077.
Malin, D., Strekalova, E., Petrovic, V., Deal, A.M., Al Ahmad, A., Adamo, B.,
Miller, C.R., Ugolkov, A., Livasy, C., Fritchie, K., et al. (2014). AlphaB-crystallin:
a novel regulator of breast cancermetastasis to the brain. Clin. Cancer Res. 20,
56–67.
Margolin, K., Ernstoff, M.S., Hamid, O., Lawrence, D., McDermott, D., Puza-
nov, I., Wolchok, J.D., Clark, J.I., Sznol, M., Logan, T.F., et al. (2012). Ipilimu-
mab in patients with melanoma and brain metastases: an open-label, phase 2
trial. Lancet Oncol. 13, 459–465.
McGowan, P.M., Simedrea, C., Ribot, E.J., Foster, P.J., Palmieri, D., Steeg,
P.S., Allan, A.L., and Chambers, A.F. (2011). Notch1 inhibition alters the
CD44hi/CD24lo population and reduces the formation of brain metastases
from breast cancer. Mol. Cancer Res. 9, 834–844.
Mendes, O., Kim, H.T., Lungu, G., and Stoica, G. (2007). MMP2 role in breast
cancer brain metastasis development and its regulation by TIMP2 and ERK1/
2. Clin. Exp. Metastasis 24, 341–351.
Mittapalli, R.K., Liu, X., Adkins, C.E., Nounou, M.I., Bohn, K.A., Terrell, T.B.,
Qhattal, H.S., Geldenhuys, W.J., Palmieri, D., Steeg, P.S., et al. (2013). Pacli-
taxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain
metastases of breast cancer model. Mol. Cancer Ther. 12, 2389–2399.
Monsky, W.L., Mouta Carreira, C., Tsuzuki, Y., Gohongi, T., Fukumura, D., and
Jain, R.K. (2002). Role of host microenvironment in angiogenesis and micro-
vascular functions in human breast cancer xenografts: mammary fat pad
versus cranial tumors. Clin. Cancer Res. 8, 1008–1013.
Morikawa, A., Peereboom, D.M., Smith, Q.R., Thorsheim, H., Lockman, P.R.,
Simmons, A.J., Weil, R.J., Tabar, V., Steeg, P.S., and Seidman, A.D. (2013).
Clinical evidence for drug penetration of capecitabine and lapatinib uptake
in resected brain metastases from women with metastatic breast cancer.
J. Clin. Oncol. 31 (May 20 Suppl), 15.
Murrell, D.H., Foster, P.J., and Chambers, A.F. (2014). Brain metastases from
breast cancer: lessons from experimental magnetic resonance imaging
studies and clinical implications. J. Mol. Med. 92, 5–12.
Nakayama, A., Takagi, S., Yusa, T., Yaguchi, M., Hayashi, A., Tamura, T., Ka-
wakita, Y., Ishikawa, T., and Ohta, Y. (2013). Antitumor activity of TAK-285, an
investigational, non-pgp substrate HER2/EGFR kinase inhibitor, in cultured tu-
mor cells, mouse and rat xenograft tumors, and in an HER2-positive brain
metastasis model. J. Cancer 4, 557–565.
Nanni, P., Nicoletti, G., Palladini, A., Croci, S., Murgo, A., Ianzano, M.L.,
Grosso, V., Stivani, V., Antognoli, A., Lamolinara, A., et al. (2012). Multiorgan
metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treat-
ment with PI3K inhibitor. PLoS ONE 7, e39626.
Neman, J., Choy, C., Kowolik, C.M., Anderson, A., Duenas, V.J., Waliany, S.,
Chen, B.T., Chen, M.Y., and Jandial, R. (2013). Co-evolution of breast-to-brain
metastasis and neural progenitor cells. Clin. Exp. Metastasis 30, 753–768.
Niikura, N., Liu, J., Hayashi, N., Mittendorf, E.A., Gong, Y., Palla, S.L., Tokuda,
Y., Gonzalez-Angulo, A.M., Hortobagyi, G.N., and Ueno, N.T. (2012). Loss of
human epidermal growth factor receptor 2 (HER2) expression in metastatic
sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 30,
593–599.
Okuda, H., Xing, F., Pandey, P.R., Sharma, S., Watabe, M., Pai, S.K., Mo, Y.Y.,
Iiizumi-Gairani, M., Hirota, S., Liu, Y., et al. (2013). miR-7 suppresses brain
metastasis of breast cancer stem-like cells by modulating KLF4. Cancer
Res. 73, 1434–1444.
Olson, E.M., Abdel-Rasoul, M., Maly, J., Wu, C.S., Lin, N.U., and Shapiro, C.L.
(2013). Incidence and risk of central nervous systemmetastases as site of first
Cancer Cell
Perspectiverecurrence in patients with HER2-positive breast cancer treated with adjuvant
trastuzumab. Ann. Oncol. 24, 1526–1533.
Ousman, S.S., and Kubes, P. (2012). Immune surveillance in the central ner-
vous system. Nat. Neurosci. 15, 1096–1101.
Palmieri, D., Lockman, P.R., Thomas, F.C., Hua, E., Herring, J., Hargrave, E.,
Johnson, M., Flores, N., Qian, Y., Vega-Valle, E., et al. (2009). Vorinostat in-
hibits brain metastatic colonization in a model of triple-negative breast cancer
and induces DNA double-strand breaks. Clin. Cancer Res. 15, 6148–6157.
Park, E.S., Kim, S.J., Kim, S.W., Yoon, S.L., Leem, S.H., Kim, S.B., Kim, S.M.,
Park, Y.Y., Cheong, J.H., Woo, H.G., et al. (2011). Cross-species hybridization
of microarrays for studying tumor transcriptome of brain metastasis. Proc.
Natl. Acad. Sci. USA 108, 17456–17461.
Pierga, J.Y., Bidard, F.C., Cropet, C., Tresca, P., Dalenc, F., Romieu, G., Cam-
pone, M., Mahier Aı¨t-Oukhatar, C., Le Rhun, E., Gonc¸alves, A., et al. (2013).
Circulating tumor cells and brain metastasis outcome in patients with HER2-
positive breast cancer: the LANDSCAPE trial. Ann. Oncol. 24, 2999–3004.
Qian, Y., Hua, E., Bisht, K., Woditschka, S., Skordos, K.W., Liewehr, D.J.,
Steinberg, S.M., Brogi, E., Akram, M.M., Killian, J.K., et al. (2011). Inhibition
of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in
the brain. Clin. Exp. Metastasis 28, 899–908.
Robert, N.J., Die´ras, V., Glaspy, J., Brufsky, A.M., Bondarenko, I., Lipatov,
O.N., Perez, E.A., Yardley, D.A., Chan, S.Y., Zhou, X., et al. (2011). RIBBON-
1: randomized, double-blind, placebo-controlled, phase III trial of chemo-
therapy with or without bevacizumab for first-line treatment of human
epidermal growth factor receptor 2-negative, locally recurrent or metastatic
breast cancer. J. Clin. Oncol. 29, 1252–1260.
Rosner, D., Nemoto, T., and Lane, W.W. (1986). Chemotherapy induces
regression of brain metastases in breast carcinoma. Cancer 58, 832–839.
Saldana, S.M., Lee, H.H., Lowery, F.J., Khotskaya, Y.B., Xia, W., Zhang, C.,
Chang, S.S., Chou, C.K., Steeg, P.S., Yu, D., and Hung, M.C. (2013). Inhibition
of type I insulin-like growth factor receptor signaling attenuates the develop-
ment of breast cancer brain metastasis. PLoS ONE 8, e73406.
Sevenich, L., Bowman, R.L., Mason, S.D., Quail, D.F., Rapaport, F., Elie, B.T.,
Brogi, E., Brastianos, P.K., Hahn,W.C., Holsinger, L.J., et al. (2014). Analysis of
tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-
promoting role for cathepsin S. Nat. Cell Biol. 16, 876–888.
Sperduto, P.W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed,
P.K., Chao, S.T., Weil, R.J., Suh, J., et al. (2012). Summary report on the
graded prognostic assessment: an accurate and facile diagnosis-specific
tool to estimate survival for patients with brain metastases. J. Clin. Oncol.
30, 419–425.
Sperduto, P.W., Kased, N., Roberge, D., Chao, S.T., Shanley, R., Luo, X.,
Sneed, P.K., Suh, J., Weil, R.J., Jensen, A.W., et al. (2013). The effect of tumor
subtype on the time from primary diagnosis to development of brain metasta-
ses and survival in patients with breast cancer. J. Neurooncol. 112, 467–472.
Stemmler, H.J., and Heinemann, V. (2008). Central nervous system metasta-
ses in HER-2-overexpressingmetastatic breast cancer: a treatment challenge.
Oncologist 13, 739–750.
Stemmler, H.J., Schmitt, M., Willems, A., Bernhard, H., Harbeck, N., and Hei-
nemann, V. (2007). Ratio of trastuzumab levels in serum and cerebrospinal
fluid is altered in HER2-positive breast cancer patients with brain metastases
and impairment of blood-brain barrier. Anticancer Drugs 18, 23–28.Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y., Honda,
N., Kodaira, M., Yamamoto, H., Yunokawa, M., et al. (2013). 64Cu-DOTA-tras-
tuzumab PET imaging in patients with HER2-positive breast cancer. J. Nucl.
Med. 54, 1869–1875.
Taskar, K.S., Rudraraju, V., Mittapalli, R.K., Samala, R., Thorsheim, H.R.,
Lockman, J., Gril, B., Hua, E., Palmieri, D., Polli, J.W., et al. (2012). Lapatinib
distribution in HER2 overexpressing experimental brain metastases of breast
cancer. Pharm. Res. 29, 770–781.
Thomas, F.C., Taskar, K., Rudraraju, V., Goda, S., Thorsheim, H.R., Gaasch,
J.A., Mittapalli, R.K., Palmieri, D., Steeg, P.S., Lockman, P.R., and Smith,
Q.R. (2009). Uptake of ANG1005, a novel paclitaxel derivative, through the
blood-brain barrier into brain and experimental brain metastases of breast
cancer. Pharm. Res. 26, 2486–2494.
Valiente, M., Obenauf, A.C., Jin, X., Chen, Q., Zhang, X.H., Lee, D.J., Chaft,
J.E., Kris, M.G., Huse, J.T., Brogi, E., and Massague´, J. (2014). Serpins pro-
mote cancer cell survival and vascular co-option in brain metastasis. Cell
156, 1002–1016.
Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram,
M., Oh, D.Y., Die´ras, V., Guardino, E., et al. (2012). Trastuzumab emtansine
for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791.
Winkler, F., Kozin, S.V., Tong, R.T., Chae, S.S., Booth, M.F., Garkavtsev, I., Xu,
L., Hicklin, D.J., Fukumura, D., di Tomaso, E., et al. (2004). Kinetics of vascular
normalization by VEGFR2 blockade governs brain tumor response to radiation:
role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer
Cell 6, 553–563.
Xiong, Z., Gharagozlou, S., Vengco, I., Chen, W., and Ohlfest, J.R. (2008).
Effective CpG immunotherapy of breast carcinoma prevents but fails to
eradicate established brain metastasis. Clin. Cancer Res. 14, 5484–5493.
Yamamoto, D., Iwase, S., Tsubota, Y., Sueoka, N., Yamamoto, C., Kitamura,
K., Odagiri, H., and Nagumo, Y. (2012). Bevacizumab in the treatment of five
patients with breast cancer and brain metastases: Japan Breast Cancer
Research Network-07 trial. Onco Targets Ther. 5, 185–189.
Yap, T.A., Vidal, L., Adam, J., Stephens, P., Spicer, J., Shaw, H., Ang, J.,
Temple, G., Bell, S., Shahidi, M., et al. (2010). Phase I trial of the irreversible
EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid
tumors. J. Clin. Oncol. 28, 3965–3972.
Yonemori, K., Tsuta, K., Ono, M., Shimizu, C., Hirakawa, A., Hasegawa, T.,
Hatanaka, Y., Narita, Y., Shibui, S., and Fujiwara, Y. (2010). Disruption of the
blood brain barrier by brain metastases of triple-negative and basal-type
breast cancer but not HER2/neu-positive breast cancer. Cancer 116, 302–308.
Zhang, M., and Olsson, Y. (1995). Reactions of astrocytes and microglial cells
around hematogenous metastases of the human brain. Expression of endo-
thelin-like immunoreactivity in reactive astrocytes and activation of microglial
cells. J. Neurol. Sci. 134, 26–32.
Zhang, L., Sullivan, P.S., Goodman, J.C., Gunaratne, P.H., and Marchetti, D.
(2011). MicroRNA-1258 suppresses breast cancer brain metastasis by target-
ing heparanase. Cancer Res. 71, 645–654.
Zhang, L., Ridgway, L.D., Wetzel, M.D., Ngo, J., Yin, W., Kumar, D., Goodman,
J.C., Groves, M.D., and Marchetti, D. (2013). The identification and character-
ization of breast cancer CTCs competent for brain metastasis. Sci. Transl.
Med. 5, 180ra148.Cancer Cell 27, February 9, 2015 ª2015 Elsevier Inc. 175
